Metaplastic carcinoma of the breast

Metaplastic carcinoma of the breast
ICD-10
ICD-9
DiseasesDB
MedlinePlus
eMedicine
MeSH ID

Metaplastic carcinoma of the breast is a rare and heterogeneous form of breast cancer characterized by the presence of both epithelial and mesenchymal components. This type of cancer is distinct from the more common types of breast cancer, such as invasive ductal carcinoma and invasive lobular carcinoma.

Epidemiology

Metaplastic carcinoma of the breast accounts for less than 1% of all breast cancers. It is more commonly diagnosed in women over the age of 50, although it can occur in younger women as well. The incidence of metaplastic carcinoma is similar across different ethnic groups.

Pathophysiology

Metaplastic carcinoma is characterized by the transformation of epithelial cells into a variety of cell types, including squamous, spindle, and chondroid cells. This transformation is thought to be driven by genetic mutations and alterations in signaling pathways that regulate cell differentiation and proliferation. The exact molecular mechanisms underlying metaplastic carcinoma are not fully understood, but they may involve dysregulation of the Wnt signaling pathway, epithelial-mesenchymal transition, and stem cell pathways.

Clinical Presentation

Patients with metaplastic carcinoma of the breast typically present with a palpable breast mass. The mass may be rapidly growing and can be associated with pain or tenderness. Skin changes, such as ulceration or erythema, may also be present. Unlike other forms of breast cancer, metaplastic carcinoma is less likely to involve the axillary lymph nodes.

Diagnosis

The diagnosis of metaplastic carcinoma is based on a combination of clinical examination, imaging studies, and histopathological evaluation. Mammography and ultrasound are commonly used imaging modalities, but the definitive diagnosis is made through a biopsy. Histologically, metaplastic carcinoma is characterized by the presence of both epithelial and mesenchymal components, which can be identified using immunohistochemistry.

Differential Diagnosis

The differential diagnosis for metaplastic carcinoma includes other types of breast cancer, such as invasive ductal carcinoma and invasive lobular carcinoma, as well as sarcoma and phyllodes tumor. Distinguishing metaplastic carcinoma from these other entities is important for determining the appropriate treatment strategy.

Treatment

The treatment of metaplastic carcinoma of the breast typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgical options include lumpectomy or mastectomy, depending on the size and location of the tumor. Chemotherapy regimens may include anthracyclines and taxanes, although the response to chemotherapy can be variable. Radiation therapy is often used as an adjunct to surgery to reduce the risk of local recurrence.

Prognosis

The prognosis for patients with metaplastic carcinoma of the breast is generally poorer than for those with more common types of breast cancer. This is due in part to the aggressive nature of the disease and its tendency to metastasize. However, the prognosis can vary depending on factors such as tumor size, grade, and the presence of metastases.

Research Directions

Ongoing research is focused on understanding the molecular and genetic basis of metaplastic carcinoma, with the goal of developing targeted therapies. Studies are also exploring the role of immunotherapy and other novel treatment approaches in improving outcomes for patients with this rare form of breast cancer.

See Also

• Breast cancer
• Invasive ductal carcinoma
• Invasive lobular carcinoma
• Sarcoma